Wednesday 30 September 2020

Swiss firm launches new rapid Covid-19 test

Bern, Switzerland, August 12, 2020

Ender diagnostics, a Swiss company specialising in the development of rapid molecular biological tests, today announced the launch of ender MASS, its second CE-marked test to detect SARS-CoV-2, the virus which causes Covid-19. 
Ender MASS is highly specific, easy-to-use and fast – providing results from a simple nasopharyngeal swab in only 30 minutes. It is designed to enable rapid diagnosis for critical settings including schools, manufacturing facilities, travel, hospitals and care homes, as well as enabling centralized laboratories to accelerate and increase throughput, said a statement.
It enables flexible testing in critical settings, with capacity to run up to eight times more tests than conventional PCRs, it said.
Reliable and rapid testing has emerged as one of the most important factors in controlling and limiting the spread of infection in the Covid-19 pandemic. One of the most critical challenges around the world has been limited testing capacity in laboratories due to shortages of viral RNA extraction kits, testing reagents and qualified technicians.
Ender diagnostics specialises in isothermal PCR-based test kits for laboratory and on-site diagnosis. It has already launched the ender LAB test in June 2020, which enables laboratories to directly detect SARS-CoV-2 on standard real-time PCR (polymerase chain reaction) devices within 30 minutes, significantly faster than currently available PCR tests, which take several hours. 
The newly approved ender MASS offers further benefits by enabling detection in a simplified and accelerated process, considerably reducing the workload for medical professionals and laboratories. It is designed to enable on-site and pop-up labs to operate rapid testing in diverse settings, potentially including travel-related locations such as airports and cruise ships. The simplified workflows and analysis mean laboratories can process up to eight times as many tests compared to conventional PCR testing over the same period, the company said.
US FDA clearance for the test is anticipated in September 2020, it said.
Tim Pfister, CEO of ender diagnostics, comments: "Constant rapid and flexible testing is the key to controlling the Covid-19 pandemic and enabling countries and economies around the world to open up and recover. Combined with a mobile lab infrastructure, the fast and easy-to-use ender MASS test would enable detection of coronavirus infection directly on-site in a wide range of locations, such as schools, hospitals, care homes, factories and in challenging locations such as airports and cruise ships prior to boarding. With a fully portable version of our testing system also advancing rapidly, ender diagnostics is well placed to make a significant contribution to helping avoid partial or large-scale lockdowns around the world."
The company is also moving ahead with development of a mobile point-of-care test for acute Covid-19 cases, called ender Mobile. Launch in Europe is planned during fall this year, it said. -TradeArabia News Service


More Health & Environment Stories

calendarCalendar of Events